Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
DVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.74 - $14.63
Previous CloseN/A
Volume272.71K
Average Volume (3M)2.64M
Market Cap
$1.71B
Enterprise Value$1.22B
Total Cash (Recent Filing)$95.88M
Total Debt (Recent Filing)$254.42M
Price to Earnings (P/E)79.2
Beta0.27
Next Earnings
May 01, 2025EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding124,070,830
10 Day Avg. Volume2,388,252
30 Day Avg. Volume2,635,365
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.18
Price to Cash Flow (P/CF)8.10
P/FCF Ratio8.10
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.38
Enterprise Value/Ebitda36.74
Forecast
1Y Price Target
$25.25Price Target Upside80.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Dynavax News
PremiumCompany Announcements
Dynavax Technologies Reports Strong Earnings and Positive Outlook
PremiumCompany Announcements
Dynavax Technologies Reports Strong Growth in 2024
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCompany guides to a significant total market opportunity for adult hepatitis B vaccines with Heplisav expected to capture at least 60% market share.
Market Share GrowthAnalyst sees continued market share gains for Heplisav as a driver for company growth.
Shareholder ReturnsDynavax announced a $200M share repurchase program, with a $100M accelerated share repurchase transaction already completed.
Bears Say
Revenue DeclineThe -10% Q/Q decline in Q4 sales is somewhat concerning.
Sales PerformanceManagement had anticipated seasonality to reduce Q4 sales by approx. 15% compared to Q3.
---
Ownership Overview
0.51% Insiders
18.61% Mutual Funds
39.43% Other Institutional Investors
15.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DVAX FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Dynavax Technologies Corp. lowest stock price was $9.74 and its highest was $14.63 in the past 12 months.
What is Dynavax Technologies Corp.’s market cap?
Dynavax Technologies Corp.’s market cap is $1.71B.
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is May 01, 2025 which is in 36 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Feb 20, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.042 by $0.008.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is 0.04.
How many shares outstanding does Dynavax Technologies Corp. have?
Dynavax Technologies Corp. has 124,070,830 shares outstanding.
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of $0.05 in its last earnings report, beating expectations of $0.042. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Currently, no hedge funds are holding shares in DVAX
---
Dynavax Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.25 (80.62% Upside)
$25.25 (80.62% Upside)
Blogger Sentiment
Neutral
DVAX Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 5.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.61%
12-Months-Change
Fundamentals
Return on Equity
4.48%
Trailing 12-Months
Asset Growth
-1.09%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
---
DVAX Company Deck
---
DVAX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a positive outlook for Dynavax, highlighted by record revenue growth, market leadership in hepatitis B vaccines, and promising clinical advancements. However, challenges remain in the approval of the hemodialysis vaccine and increasing R&D expenses.Read More>---
DVAX Stock 12 Month Forecast
Average Price Target
$25.25
▲(80.62% Upside)
Technical Analysis
Best Analysts Covering DVAX
1 Year
1 Year Success Rate
18/28 ratings generated profit
1 Year Average Return
+42.71%
reiterated a buy rating last month
Copying Matt Phipps's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +42.71% per trade.
---